Research analysts who have asked questions during IceCure Medical earnings calls.
AV
Anthony Vendetti
Maxim Group
6 questions for ICCM
Also covers: AEMD, AGFY, BHST +19 more
Eduardo Martinez-Montes
H.C. Wainwright & Co., LLC
3 questions for ICCM
Also covers: ANGO, BLFS, CDXC +8 more
Kemp Dolliver
Brookline Capital Markets
3 questions for ICCM
Also covers: BIOX, EYEN, IMNN +4 more
YC
Yi Chen
H.C. Wainwright & Co.
2 questions for ICCM
Also covers: ANGO, APDN, BLFS +22 more
BK
Brian Kemp Dolliver
Brookline Capital Markets, LLC
1 question for ICCM
Also covers: , BIOX, DARE +6 more
Recent press releases and 8-K filings for ICCM.
IceCure Medical's Cryoablation Technology Included in Proposed ASBrS Breast Cancer Treatment Guidelines
ICCM
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- The American Society of Breast Surgeons (ASBrS) is in the final stage of updating its guidelines, which are expected to include cryoablation for the local treatment of breast cancer in specific patient populations and for small benign breast tumors.
- This proposed update aligns with the U.S. FDA's marketing authorization granted in October 2025 for cryoablation in breast cancer treatment, making IceCure's ProSense® system the first and only device with this authorization.
- IceCure Medical anticipates that the inclusion of cryoablation in these guidelines will lead to accelerated commercial adoption of its ProSense® system and expanded reimbursement coverage.
- The ProSense® system addresses an estimated 200,000 women annually in the U.S. breast cryoablation patient population.
Jan 28, 2026, 1:30 PM
IceCure Medical Reports Record 2025 ProSense Sales and FDA Authorization
ICCM
Earnings
Guidance Update
Product Launch
- IceCure Medical Ltd. reported record ProSense® sales of approximately $3.4 million for the full year ended December 31, 2025, with a cash and cash equivalents balance of approximately $8.9 million as of December 31, 2025.
- The company received FDA marketing authorization in October 2025 for ProSense® for the local treatment of low-risk breast cancer in women aged 70 and above, addressing a U.S. patient population of approximately 200,000 women annually.
- IceCure anticipates higher ProSense® system and cryoprobe sales in 2026 and expects additional reimbursement coverage, with the CPT III code increasing to $4,049 effective January 2026.
Jan 12, 2026, 1:45 PM
IceCure Medical Reports Record 2025 ProSense Sales and FDA Marketing Authorization
ICCM
Earnings
Revenue Acceleration/Inflection
Product Launch
- IceCure Medical reported preliminary, unaudited record ProSense® sales of approximately $3.4 million for the year ended December 31, 2025, driven by growing demand in the U.S. and record sales in Europe.
- The company received FDA marketing authorization in October 2025 for ProSense® for the local treatment of low-risk breast cancer in women aged 70 and above, which contributed to record fourth-quarter results in North America.
- As of December 31, 2025, IceCure's cash and cash equivalents balance was approximately $8.9 million.
- ProSense® addresses a U.S. patient population of approximately 200,000 women annually for breast cryoablation, and the company anticipates higher sales and potential additional reimbursement coverage in 2026.
Jan 12, 2026, 1:30 PM
IceCure Medical expects record Q4 North American sales following FDA clearance
ICCM
Revenue Acceleration/Inflection
Product Launch
Guidance Update
- IceCure Medical Ltd. expects to report record fourth-quarter sales in North America, representing a significant increase compared to the same period last year.
- This anticipated sales growth is driven by the U.S. Food and Drug Administration's (FDA) marketing authorization of ProSense® for the local treatment of low-risk breast cancer in women aged 70 and above, granted in October 2025.
- The company is experiencing a surge of interest for its ProSense® console and disposable cryoprobes, leading to sales and installations at new locations, including highly regarded medical institutions.
- IceCure plans to report preliminary top-line revenue results in January 2026, followed by its full annual report on Form 20-F in April 2026.
Dec 17, 2025, 1:45 PM
IceCure Medical Expects Record Fourth Quarter North American Sales
ICCM
Revenue Acceleration/Inflection
Product Launch
Guidance Update
- IceCure Medical is expecting to report a significant increase in fourth-quarter North American sales, which would represent record levels for the company.
- This anticipated growth follows the U.S. Food and Drug Administration's (FDA) marketing authorization in October 2025 for ProSense® for the local treatment of low-risk breast cancer in women aged 70 and above.
- The company is observing a surge of interest for the ProSense® console and cryoprobes, with sales and installations at new locations across North America, including highly regarded medical institutions.
- IceCure plans to report preliminary top-line revenue results in January 2026, followed by its full annual report on Form 20-F in April 2026.
Dec 17, 2025, 1:30 PM
IceCure Medical's ProSense Cryoablation Featured in Breast Cancer Studies at RSNA 2025
ICCM
New Projects/Investments
Product Launch
- IceCure Medical Ltd.'s ProSense® Cryoablation technology was featured in four independent breast cancer studies presented at the Radiological Society of North America (RSNA) 2025 Annual Meeting, which took place from November 30 to December 4, 2025.
- The presented abstracts included three studies involving 263 patients, adding to the evidence supporting broader adoption of ProSense®.
- One study highlighted that Percutaneous Cryoablation (PCA) was successful in 100% of luminal cancers up to 2.5 cm in non-surgical patients.
- Another study indicated that Cryoablation combined with hormonal therapy significantly reduces tumor size and residual disease more effectively than hormonal therapy alone.
- IceCure's CEO noted growing interest in ProSense® following the U.S. FDA's recent marketing approval in low-risk breast cancer.
Dec 10, 2025, 1:45 PM
IceCure Medical's ProSense® Featured in Four Independent Breast Cancer Studies at RSNA 2025
ICCM
Product Launch
New Projects/Investments
- IceCure Medical's ProSense® cryoablation technology was featured in four independent studies presented at the Radiological Society of North America's (RSNA) Annual Meeting from November 30 to December 4, 2025, adding to evidence supporting its adoption.
- One study reported 100% success of percutaneous cryoablation (PCA) in luminal cancers up to 2.5 cm in non-surgical breast cancer patients.
- Another study indicated that Cryoablation combined with hormonal therapy significantly reduced tumor size and residual disease more effectively than therapy alone in surgery-ineligible patients.
- ProSense® is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above.
Dec 10, 2025, 1:30 PM
IceCure Medical Announces Q3 2025 Financial Results and FDA Marketing Authorization for ProSense
ICCM
Earnings
Product Launch
Guidance Update
- For the nine months ended September 30, 2025, IceCure Medical reported revenue of $2.1 million, a decrease from $2.4 million in the same period of 2024, with gross profit falling to $626,000 from $1,034,000.
- In October 2025, the company received FDA marketing authorization for its ProSense cryoablation system to treat low-risk breast cancer, targeting an addressable market of over 200,000 patients annually in the U.S..
- IceCure's cash, cash equivalents, and short-term deposits increased to $10 million as of September 30, 2025, from $7.6 million at December 31, 2024, significantly bolstered by $10 million from a rights offering and $5.87 million from an at-the-market offering.
- ProSense received approval in Switzerland, and the company's Japanese partner, Terumo Corporation, plans to submit a regulatory application for breast cancer treatment in H1 2026.
- The company expects to receive final FDA approval for its post-market study protocol by end of 2025 or early 2026, with the first patient recruitment anticipated by summer 2026.
Nov 19, 2025, 3:00 PM
IceCure Medical Announces Q3 2025 Results and FDA Marketing Authorization for ProSense
ICCM
Earnings
Product Launch
New Projects/Investments
- IceCure Medical received FDA marketing authorization in October 2025 for its ProSense cryoablation system to treat low-risk breast cancer.
- The company estimates a significant U.S. addressable market of approximately 200,000 patients annually for ProSense, including women aged 70 and older with specific tumor characteristics, patients not eligible for surgery, and those with benign breast tumors.
- For the nine months ended September 30, 2025, revenue was $2.1 million and net loss was $10.8 million ($0.18 per share).
- As of October 31, 2025, IceCure Medical held $11.8 million in cash, cash equivalents, and short-term deposits, bolstered by a $10 million rights offering in July 2025 and $5.87 million from an at-the-market offering.
Nov 19, 2025, 3:00 PM
IceCure Medical Receives FDA Authorization for ProSense and Reports Q3 2025 Financials
ICCM
Product Launch
Earnings
Revenue Acceleration/Inflection
- IceCure Medical received FDA marketing authorization in October 2025 for its ProSense cryoablation system to treat low-risk breast cancer, which the company considers its most significant milestone to date.
- The FDA authorization targets a U.S. addressable market of approximately 200,000 patients annually, including women aged 70 and older with small tumors, those not eligible for surgery, and patients with benign breast tumors.
- For the nine months ended September 30, 2025, revenue was $2.1 million, a decrease from $2.4 million in the prior year, and the company reported a net loss of $10.8 million or $0.18 per share.
- As of September 30, 2025, cash, cash equivalents, and short-term deposits totaled $10 million, increasing to $11.8 million by October 31, 2025, following a $10 million rights offering and $5.87 million from an at-the-market offering.
Nov 19, 2025, 3:00 PM
Quarterly earnings call transcripts for IceCure Medical.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more